Compare Incyte Corporation (INCY) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Norwegian Cruise Line Holdings Ltd — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Norwegian Cruise Line Holdings Ltd trades at $18.91 (market cap $8.59B). The key difference: Incyte Corporation is far larger — about 2.9× Norwegian Cruise Line Holdings Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| INCY | NCLH | |
|---|---|---|
Market Cap | $24.54B | $8.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $26.94 |
52-Week Low | $81.61 | $14.79 |
Enterprise Value | $20.04B | $23.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
NCLH trades at $18.93, up 2.05% today, with a bearish technical signal but strong fundamentals including a P/E of 11.33 and net income margin of 7.49%. Recent Q2 2026 earnings beat expectations at $0.48 per share, though revenue growth faces headwinds from high costs. Analyst consensus is a buy with a $20.73 price target, but news highlights concerns over fuel expenses and demand.
The outlook is mixed: valuation metrics suggest upside potential, but risks from macroeconomic pressures and execution challenges persist. Investors may find opportunity if turnaround plans gain traction, yet volatility from operational costs and travel demand fluctuations warrants caution for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
